[
    [
        {
            "time": "2021-09-15",
            "original_text": "Novartis' (NVS) NSCLC Drug Fails to Meet Primary Endpoint",
            "features": {
                "keywords": [
                    "Novartis",
                    "NSCLC",
                    "Drug",
                    "Fails",
                    "Primary",
                    "Endpoint"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 2,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-09-16",
            "original_text": "Novartis Canakinumab Fails To Improve Survival In Late-Stage Lung Cancer Trial",
            "features": {
                "keywords": [
                    "Novartis",
                    "Canakinumab",
                    "Fails",
                    "Survival",
                    "Late-Stage",
                    "Lung",
                    "Cancer",
                    "Trial"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "false",
                "ts_effect_direction": "none"
            },
            "scores": {
                "News_content": "Novartis Canakinumab Fails To Improve Survival In Late-Stage Lung Cancer Trial",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 10
            }
        },
        {
            "time": "2021-09-17",
            "original_text": "The Daily Biotech Pulse: Regulatory Setback For Acadia, Lilly Forges Diabetes Antibody Treatment Collaboration, Aytu's Positive COVID-19 Data",
            "features": {
                "keywords": [
                    "Regulatory",
                    "Setback",
                    "Acadia",
                    "Lilly",
                    "Diabetes",
                    "Antibody",
                    "Treatment",
                    "Collaboration",
                    "Aytu",
                    "Positive",
                    "COVID-19",
                    "Data"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "biotech"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 6,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-09-18",
            "original_text": "Molecular Partners/Novartis's COVID-19 Antiviral Therapy Shows Encouraging Action Early-Stage Study",
            "features": {
                "keywords": [
                    "Molecular",
                    "Partners",
                    "Novartis",
                    "COVID-19",
                    "Antiviral",
                    "Therapy",
                    "Encouraging",
                    "Action",
                    "Early-Stage",
                    "Study"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2021-09-19",
            "original_text": "Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer",
            "features": {
                "keywords": [
                    "Novartis",
                    "Phase",
                    "III",
                    "canakinumab",
                    "ACZ885",
                    "second",
                    "third-line",
                    "treatment",
                    "chemotherapy",
                    "non-small",
                    "cell",
                    "lung",
                    "cancer"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        }
    ]
]